News Headlines Article

The obscurity of drug spending in Medi-Cal

California will be a flashpoint in the policy debate this year around reining in the cost of high-priced prescription drugs. A measure expected to be before voters this November would restrict the state’s drug payment to no more than the lowest price paid for the same drug by the U.S. Department of Veterans Affairs. And an unlikely coalition of health insurers, labor and consumer advocates promises to keep pushing for controls on high-cost drugs, after a state Assembly bill that would have forced pharmaceutical manufacturers to disclose their costs stalled in committee last week.